Nathan Pennell, MD, Oncology, Cleveland, OH

NathanAPennellMDPhD, FASCO

Oncology Cleveland, OH

Hematologic Oncology, Thoracic Cancer

Professor of Medicine, Director of the Lung Cancer Medical Oncology Program, Vice Chair of Clinical Research, Cleveland Clinic Taussig Cancer Institute

Dr. Pennell is on Doximity

As a Doximity member you'll join over a million verified healthcare professionals in a private, secure network.

  • Connect with other colleagues in the same hospital or clinic
  • Search all U.S. specialist profiles and refer a patient
  • Read the latest clinical news and earn CME/CEU credits

See Dr. Pennell's full profile

Already have an account?

Summary

  • I am the Vice Chair of Clinical Research as well Director of the lung cancer medical oncology program at the Cleveland Clinic Taussig Cancer Institute, where I specialize in the care of patients with thoracic malignancies, including lung cancer and mesothelioma. I also perform clinical research in lung cancer and am active in healthcare social media.

    I am also active in patient and graduate medical education. I serve as co-section editor for lung cancer for the Oncologist and am the Associate Editor of the American Society of Clinical Oncology (ASCO) Education Book.

    I serve as consultant editor of the Journal of Oncology Practice (JOP), in charge of podcast production.

Education & Training

  • Dana-Farber Cancer InstituteFellowship, Medical Oncology, 2005 - 2007
  • Brigham and Women's Hospital
    Brigham and Women's HospitalResidency, Internal Medicine, 2002 - 2005
  • University of Florida College of Medicine
    University of Florida College of MedicineClass of 2002
  • University of FloridaPhD, Neuroscience, 1993 - 1998
  • University of North CarolinaBS, Biology, 1989 - 1993

Certifications & Licensure

  • OH State Medical License
    OH State Medical License 2008 - 2022
  • American Board of Internal Medicine Medical Oncology

Awards, Honors, & Recognition

  • Fellow of the American Society of Clinical Oncology ASCO, 2020
  • Associate Editor, ASCO Educational Book ASCO
  • Consultant Editor Journal of Oncology Practice
  • Join now to see all

Clinical Trials

Publications & Presentations

PubMed

Journal Articles

  • Adjuvant Targeted Therapy for Patients with Epidermal Growth Factor Receptor–Mutant Lung Cancer  
    Nathan Pennell, MD, JAMA Oncology
  • ALK Status Testing in Non-small Cell Lung Carcinoma by FISH on ThinPrep Slides with Cytology Material  
    Minca EC, Lanigan C, Reynolds JP, Wang Z, Ma PC, Cicenia J, Almeida FA, Pennell NA, Tubbs RR, J Thor Onc, 1/1/2014
  • High MET Receptor Expression but not Gene Amplification in ALK 2p23 Rearrangement Positive Non-Small Cell Lung Cancer  
    Feng Y, Minca EC, Lanigan C, Liu A, Zhang W, Yin L, Pennell NA, Farver C, Tubbs R, Ma PC, J Thor Onc, 1/1/2014
  • Join now to see all

Books/Book Chapters

Abstracts/Posters

  • Molecular Subtyping to Predict Risk of Venous Thromboembolism in Patients with Advanced Lung Adenocarcinoma: A Cohort Study
    Nathan A Pennell, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
  • EGFR Mutational Analysis by Allele Specific PCR on Fine Needle Aspiration and Biopsy Derived Samples of Non-Small Cell Lung Carcinoma
    Minca EC, Brainard J, MacNamara S, Farver C, Ma PC, Arrossi V, Pennell N, Tubbs RR, USCAP Annual Meeting, 1/1/2014
  • Circulating Tumor Cells Enrichment and Characterization in ALK-translocation Positive Lung Cancer
    PC Ma, L Yin, P Joshi, Y Feng, B Jacobs, W Zhang, M Shapiro, M McNamara, N Hashemi Sadraei, N Pennell, E B, M Zborowski, Proc Amer Soc Clin Onc, 1/1/2014
  • Join now to see all

Lectures

  • Guidelines, Barriers, Access to Molecular Testing in NSCLC 
    ASCO Annual Meeting 2019 - Chicago, IL - 5/31/2019
  • Assessment and Diagnostics of Newly Diagnosed Patients With Advanced Non-Small Cell Lung Cancer 
    2018 ASCO Annual Meeting - Chicago, Illinois - 06/1/2018
  • Circulating Tumor Cells Detection and Molecular Characterization of ALK(2p23)-Fusion Non-Small Cell Lung Cancer 
    Sydney - 1/1/2013
  • Join now to see all

Other

Authored Content

  • Efficacy of Selpercatinib in RET Fusion–Positive Non–Small-Cell Lung CancerAugust 2020
  • Efficacy of Selpercatinib in RET Fusion–Positive Non–Small-Cell Lung CancerAugust 2020
  • Efficacy of Selpercatinib in RET Fusion–Positive Non–Small-Cell Lung CancerAugust 2020

Press Mentions

  • Expert Talks Liquid Biopsies, Molecular Testing in Lung Cancer
    Expert Talks Liquid Biopsies, Molecular Testing in Lung CancerJanuary 3rd, 2020
  • Liquid Biopsies Are Link to Increasing Molecular Testing in Lung Cancer
    Liquid Biopsies Are Link to Increasing Molecular Testing in Lung CancerJanuary 2nd, 2020
  • She Never Smoked -- and Got Lung Cancer in Her 40s
    She Never Smoked -- and Got Lung Cancer in Her 40sDecember 17th, 2019
  • Join now to see all

Professional Memberships